Latest Headlines

Latest Headlines

India's patent office nixes Takeda diabetes application

The patent office in India has slapped down an application from Tokyo-based Takeda Pharmaceutical for its single-dose Type 2 diabetes treatment dipeptidyl peptidase 4 (DPP-4) inhibitor.

Science team says they've taken another step toward a potential cure for diabetes

Building on years of work on developing new insulin-producing cells that could one day control glucose levels and cure diabetes, a group of investigators led by scientists at MIT and Boston Children's Hospital say they've developed a promising new gel capsule that protected the cells from an immune system assault.

Sanofi and LG Life Sciences bicker over diabetes drug marketing, report says

A partnership dispute over co-promotion duties between LG Life Sciences and Sanofi-Aventis Korea, the local affiliate of France's Sanofi, threatens to spill over into the courts if the two companies cannot settle their differences.

Mayo Clinic researchers tackle age-related stem cell dysfunction and metabolic disease

In one of the latest examples of the growing focus on anti-aging research, researchers at the Mayo Clinic have taken what they hope is the first step in reversing age-related stem cell dysfunction and metabolic disease.

Japan's Mitshubishi Pharma loses Indian diabetes case

India's patent office dealt a blow to Mitsubishi Pharma by denying the Japanese company's application to patent the new diabetes drug teneligliptin, which will allow generic makers to move ahead with their plans to manufacture and market the drug.

New screening tech at Scripps spotlights diabetes drug candidates

The Scripps Research Institute has used a new drug screening platform to identify a drug which researchers believe has strong potential for treating diabetes.

Lyxumia's CV results may help Sanofi's case for approval, but they won't score it points against SGLT2s

The  New England Journal of Medicine  has laid out the data from a cardiovascular outcomes trial of Sanofi's GLP-1 diabetes hopeful Lyxumia, and the good news for the French drugmaker is that the drug didn't raise the rate of major cardiovascular events in patients with acute coronary syndrome. But it didn't lower it, either.

India's gliptin market ready for a shakeup by Zydus at 11 U.S. cents a pill

India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version of the disease.

Merck KGaA JV set to start producing drugs in remote Algerian village

Germany's Merck KGaA has for some years been taking steps to cash in on the growing population in emerging markets of people needing treatment for diabetes and associated conditions, sometimes building plants to make its diabetes treatments locally. Working through a joint venture, a plant is starting production in North Africa.

Sanofi bets another $1.7B on diabetes to pad its lagging pipeline

Sanofi, stockpiling diabetes assets with eyes on Novo Nordisk and Eli Lilly, inked a deal worth up to $1.7 billion to bring in a late-stage treatment for the disease, partnering up with Lexicon Pharmaceuticals.